Peptide research 2026 year in review FDA PCAC CagriSema regulatory clinical developments Durham Peptides Canada 2026 has been one of the most consequential years in peptide research in recent memory — major regulatory shifts at the FDA, headline clinical readouts from advanced metabolic-peptide trials, and continued category development across both established and emerging compounds. This article is a research-focused year-in-review of what actually happened, with every claim